Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GI-4000 in KRAS mutant cancers.

Expert opinion on investigational drugs - 1 Feb 2014

Shahda Safi, O'Neil Bert

Abstract excerpt

INTRODUCTION: Cancer develops mainly as a result of accumulating mutations in genes controlling cell growth regulation. RAS is one of the most commonly mutated genes in cancer. While agents targeting the signaling aspects of RAS have met with some success, resistance to therapy remains a major is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Vaccines
Share to KRAS gene
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Saccharomyces cerevisiae

Source

Identifiers

PMID: 24372276
DOI: 10.1517/13543784.2014.876408

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Prepared record publication-24372276-2026-09-05.1. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GI-4000 in KRAS mutant cancers.PMID 24372276Read ↗

Cancer vaccines: Targeting KRAS-driven cancers.Semantic proximity Read ↗

KRAS mutation: from undruggable to druggable in cancerSemantic proximity Read ↗

Drugging KRAS: current perspectives and state-of-art review.Semantic proximity Read ↗

KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of ImmunotherapySemantic proximity Read ↗

Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors.Semantic proximity Read ↗

Immune modulatory effects of oncogenic KRAS in cancerSemantic proximity Read ↗

The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?Semantic proximity Read ↗

Targeting the KRAS Oncogene for Patients with Metastatic Colorectal CancerSemantic proximity Read ↗

Mutated RAS: Targeting the “Untargetable” with T CellsSemantic proximity Read ↗

Targeting mutant KRAS.Semantic proximity Read ↗

Unlocking KRAS: Navigating Its Molecular Biology and Treatment Landscape Among Gastrointestinal Malignancies.Semantic proximity Read ↗

Advancements in gene therapies targeting mutant KRAS in cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.